What is reference pricing?
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,
This new DMP for obesity should consider and combine various therapeutic approaches to offer the best possible care, treat patients with obesity
Early benefit assessments are completed within 12 months, while method assessments used to take around 3 years. In 2020, the G-BA introduced
Since 2011, 7 new laws were added to AMNOG to dictate the early benefit assessment of drugs. Therefore, it is often called